BIM-018
BIM-018 is a synthetic cannabinoid that is structurally related to JWH-018, which is known for its potent psychoactive effects. BIM-018 is a full agonist at both the CB1 and CB2 cannabinoid receptors, with a binding affinity of 1.2 nM at CB1 and 1.1 nM at CB2. It is one of the few synthetic cannabinoids to have been studied in animals, with studies showing it to have similar effects to THC, the main active component of cannabis.
Chemistry[edit]
BIM-018 is a derivative of JWH-018, with a phenylacetyl group replacing the naphthyl group of JWH-018. This change in structure results in a compound with similar binding affinity to the cannabinoid receptors, but with a different chemical structure. The exact synthesis of BIM-018 is not publicly available, but it is likely to involve a similar process to the synthesis of JWH-018, involving the reaction of a suitable phenylacetyl halide with a suitable indole derivative.
Pharmacology[edit]
BIM-018 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a slightly higher affinity for the CB1 receptor. This is similar to the action of THC, which is also a full agonist at both receptors. The psychoactive effects of BIM-018 are likely to be due to its action at the CB1 receptor, which is primarily located in the brain. The CB2 receptor is primarily located in the immune system, and the effects of BIM-018 at this receptor are less well understood.
Effects[edit]
The effects of BIM-018 are similar to those of THC and other synthetic cannabinoids, and include euphoria, relaxation, and changes in perception. However, as with all synthetic cannabinoids, the effects can be unpredictable and can vary greatly between individuals. There have been reports of severe adverse effects, including psychosis, seizures, and cardiac arrest, particularly when BIM-018 is used in high doses or in combination with other substances.
Legal Status[edit]
The legal status of BIM-018 varies by country. In many countries, including the United States, it is classified as a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess. In other countries, it may be legal or regulated under analogue laws.
See Also[edit]
-
BIM-018 Structure
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
